Mannosylated solid lipid nanoparticles for lung-targeted delivery of Paclitaxel

Drug Development and Industrial Pharmacy

Volumn 41, Issue 4, 2015, Pages 640-649

  Sahu, Piyush Kumar ^a   Mishra, Deepak Kumar ^a   Jain, Nivrati ^a   Rajoriya, Vaibhav ^a   Jain, Ashish Kumar ^a  

^a ADINA Institute of Pharmaceutical Sciences   (India)

Author keywords

Lung cancer targeting; Mannosylation; Paclitaxel; Solid lipid nanoparticles; SRB assay

Indexed keywords

MANNOSE; PACLITAXEL; SOLID LIPID NANOPARTICLE; 1,2-DISTEAROYLPHOSPHATIDYLETHANOLAMINE; ANTINEOPLASTIC AGENT; NANOPARTICLE; PHOSPHATIDYLETHANOLAMINE; TRIACYLGLYCEROL; TRISTEARIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG RELEASE; ERYTHROCYTE; FLUORESCENCE MICROSCOPY; HEMOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG; LUNG ALVEOLUS CELL; LUNG CANCER; NONHUMAN; PARTICLE SIZE; RAT; RING OPENING; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; ABSORPTION; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG FORMULATION; DRUG SCREENING; DRUG STABILITY; DRUG STORAGE; LUNG ALVEOLUS; LUNG NEOPLASMS; MALE; METABOLISM; PATHOLOGY; SURFACE PROPERTY; TISSUE DISTRIBUTION; TUMOR CELL LINE; ULTRASTRUCTURE;

ABSORPTION, PHYSIOLOGICAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; CELL LINE, TUMOR; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; DRUG STABILITY; DRUG STORAGE; HUMANS; LUNG NEOPLASMS; MALE; MANNOSE; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE; PHOSPHATIDYLETHANOLAMINES; PULMONARY ALVEOLI; RATS; SURFACE PROPERTIES; TISSUE DISTRIBUTION; TRIGLYCERIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929088696     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2014.891130     Document Type: Article

References (22)

1. Pazdur R, Wagman LD, Camphausen KA, Hoskins JA. Cancer management: a multidisciplinary approach. New Delhi: CBS Publisher and Distributor; 2009:91-8
2. Dennis JW, Granovsky M, Warren CE. Glycoprotein glycosylation and cancer progression. Biochim Biophys Acta 1999;14: 21-34
3. Verma RK, Kaur J, Kumar K, et al. Intracellular time course pharmacokinetics and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. Antimicrob Agents Chemother 2008;52:3195-201
4. Budzynska R, Nevozhay D, Kanska U, et al. Antitumor activity of mannan-methotrexate conjugated in vitro and in vivo. Oncol Res 2007;16:415-21
5. Nag A, Ghosh RC. Assessment of targeting potential of galactosylated and mannosylated sterically stabilized liposomes to different cell types of mouse liver. J Drug Target 1999;6: 427-38
6. Jain A, Agarwal A, Majumder S, et al. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J Control Rel 2010;148:359-67
7. Shaji J, Jain V. Solid lipid nanoparticles: a novel carrier for chemotherapy. Int J Pharm 2010;2:8-17
8. Lim SJ, Lee MK, Kim CK. Altered chemical and biological activities of all-trans retinoic acid incorporated in solid lipid nanoparticle powders. J Control Rel 2004;100:53-61
9. Bisht S, Maitra A. Dextran-doxorubicin/chitosan nanoparticles for solid tumor therapy. Adv Rev 2000;91:415-25
10. Li R, Eun JS, Lee MK. Pharmacokinetics and biodistribution of paclitaxel loaded in pegylated solid lipid nanoparticles after intravenous administration. Arch Pharm Res 2011;34:331-7
11. Zhang YL, Zhang ZH, Jiang TY, et al. Cell uptake of paclitaxel solid lipid nanoparticles modified by cell-penetrating peptides in A549 cells. Die Pharmazie 2013;68:47-53
12. Yao HJ, Ju RJ, Wang XX, et al. The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancer by oral delivery. Biomaterials 2011;32: 3285-302
13. Schubert MA, Muller-Goymann CC. Solvent injection as a new approach for manufacturing lipid nanoparticles evaluation of the method and process parameters. Eur J Pharm Biopharm 2003;55: 125-31
14. Jain AK, Jain SK. Development and characterization of nanolipobeads based dual drug delivery system for H. Pylori targeting. J Drug Targ 2013;21:593-603
15. Utreja S, Jain NK. Solid lipid nanoparticles. In: Jain NK, ed. Advances in controlled and novel drug delivery. New Delhi: CBS Publishers and Distributors; 2001:408-24
16. Fry DW, White JC, Goldman ID. Rapid separation of low molecular weight solute from liposomes without dilution. Anal Biochem 1978; 890:809-15
17. Bocca C, Caputo O, Cavalli R, et al. Phagocytic uptake of fluorescent stealth and non-stealth solid lipid nanoparticles. Int J Pharm 1998;175:185-93
18. Vanicha V, Kanyawim K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nature Protocol 2006;1:1112-16
19. Papazisis KT, Geromichalos GD, Kortsaris KA, Dimitriadis AH. Optimization of the sulforhodamine B colorimetric assay. J Immunol Meth 1997; 208:151-8
20. Duncan R, Bhakoo M, Riley ML, Tuboku-Metzger A. Soluble polymeric drug carriers haematocompatibility. In: Gomez-Fernandez JC, Chapman D, eds. Progress in membrane biotechnology. Birkhauser: Verlag Basel; 1991:121-9
21. Bhadra D, Bhadra S, Jain S, Jain NK. PEGylated dendritic nanoparticulate carrier of 5-fluorouracil. Int J Pharm 2003;257: 111-24
22. Reddy LH, Murthy RSR. Pharmacokinetics and biodistribution studies of doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles synthesized by two different techniques. Biomed Paper 2004; 148:161-6.